{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:47:11Z","timestamp":1753876031093,"version":"3.41.2"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The usefulness of leucine-rich alpha 2 glycoprotein (LRG) to evaluate Crohn\u2019s disease (CD) activity differs among various intestinal lesions. We aimed to evaluate the association between endoscopic disease activity based on the Simple Endoscopic Score for Crohn\u2019s disease (SES-CD) and LRG level separately for small intestinal and colonic lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We examined the correlation between LRG level and SES-CD and performed receiver operating characteristic (ROC) analysis to determine the LRG cutoff value in 141 patients who underwent endoscopy (total 235 measurements). Furthermore, the LRG cutoff value was analyzed by comparing small intestinal and colonic lesions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>LRG levels were significantly higher in patients without mucosal healing than in those with mucosal healing (15.9 \u03bcg\/mL vs 10.5 \u03bcg\/mL, P &amp;lt; .0001). The LRG cutoff value for mucosal healing was 14.3 \u03bcg\/mL (area under the ROC curve [AUC]: 0.80; sensitivity: 0.89; specificity: 0.63). The LRG cutoff value for patients with type L1 was 14.3 \u03bcg\/mL (sensitivity: 0.91; specificity: 0.53), and that for patients with type L2 was 14.0 \u03bcg\/mL (sensitivity: 0.95; specificity: 0.73). The diagnostic performance (AUC) of LRG and C-reactive protein (CRP) for mucosal healing was, respectively, 0.75 and 0.60 (P = 0.01) in patients with type L1 and 0.80 and 0.85 (P = 0.90) in patients with type L2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The optimal LRG cutoff value for evaluating mucosal healing in CD is 14.3 \u03bcg\/mL. LRG is more useful than CRP for predicting mucosal healing in patients with type L1. The superiority of LRG to CRP differs between small intestinal and colonic lesions.<\/jats:p><\/jats:sec>","DOI":"10.1093\/crocol\/otad028","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T11:45:21Z","timestamp":1684842321000},"source":"Crossref","is-referenced-by-count":4,"title":["Usefulness of Serum Leucine-rich Alpha 2 Glycoprotein in Crohn\u2019s Disease: Is There Any Difference between Small Intestine and Colonic Lesions?"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7802-3980","authenticated-orcid":false,"given":"Satohiro","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Jichi Medical University Saitama Medical Center From the , 1-847 Amanuma, Omiya, Saitama, Saitama 330-8503 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirosato","family":"Mashima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Jichi Medical University Saitama Medical Center From the , 1-847 Amanuma, Omiya, Saitama, Saitama 330-8503 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"issue":"6","key":"2023060914134201500_CIT0001","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol."},{"key":"2023060914134201500_CIT0002","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","article-title":"Risk of surgery for in\ufb02ammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies","volume":"145","author":"Frolkis","year":"2013","journal-title":"Gastroenterology."},{"key":"2023060914134201500_CIT0003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2016.524","article-title":"Improvements in the long-term outcome of Crohn\u2019s disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort","volume":"112","author":"Jeuring","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"2023060914134201500_CIT0004","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in in\ufb02ammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"2023060914134201500_CIT0005","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/ibd.21034","article-title":"Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn\u2019s disease","volume":"15","author":"D\u2019Haens","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"2023060914134201500_CIT0006","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort","volume":"133","author":"Fr\u00f8slie","year":"2007","journal-title":"Gastroenterology."},{"key":"2023060914134201500_CIT0007","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ecco-jcc\/jjx124","article-title":"Sepsis markers soluble IL-2 receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory bowel disease","volume":"12","author":"Hosomi","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2023060914134201500_CIT0008","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1097\/MIB.0000000000001202","article-title":"Calprotectin more accurately predicts endoscopic remission of Crohn\u2019s disease than serological biomarkers evaluated using balloon-assisted enteroscopy","volume":"23","author":"Kawashima","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2023060914134201500_CIT0009","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis","volume":"110","author":"Mosli","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"2023060914134201500_CIT0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices","volume":"103","author":"Langhorst","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"2023060914134201500_CIT0011","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn\u2019s disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"2023060914134201500_CIT0012","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.118919","article-title":"iTRAQ-based proteomic identi\ufb01cation of leucine-rich \u03b1-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases","volume":"69","author":"Serada","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"2023060914134201500_CIT0013","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/ibd.22936","article-title":"Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis","volume":"18","author":"Serada","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2023060914134201500_CIT0014","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00535-021-01793-0","article-title":"Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study","volume":"56","author":"Shinzaki","year":"2021","journal-title":"J Gastroenterol."},{"key":"2023060914134201500_CIT0015","doi-asserted-by":"crossref","first-page":"11086","DOI":"10.1038\/s41598-021-90441-x","article-title":"Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease","volume":"11","author":"Yasutomi","year":"2021","journal-title":"Sci Rep."},{"key":"2023060914134201500_CIT0016","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3390\/jcm11092494","article-title":"Serum leucine-rich alpha-2 glycoprotein in quiescent Crohn\u2019s disease as a potential surrogate marker for small-bowel ulceration detected by capsule endoscopy","volume":"11","author":"Omori","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"2023060914134201500_CIT0017","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ibd\/izac076","article-title":"Accuracy of serum leucine-rich alpha-2 glycoprotein in evaluating endoscopic disease activity in Crohn\u2019s disease","volume":"29","author":"Kawamura","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2023060914134201500_CIT0018","doi-asserted-by":"crossref","first-page":"e1196","DOI":"10.1016\/j.cgh.2021.06.036","article-title":"Serum leucine-rich \u03b12 glycoprotein: a novel biomarker for small bowel mucosal activity in Crohn\u2019s disease","volume":"20","author":"Kawamoto","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023060914134201500_CIT0019","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/jgh.15907","article-title":"Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn\u2019s disease","volume":"37","author":"Abe","year":"2022","journal-title":"J Gastroenterol Hepatol."},{"key":"2023060914134201500_CIT0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology."},{"key":"2023060914134201500_CIT0021","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc."},{"key":"2023060914134201500_CIT0022","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1053\/j.gastro.2014.04.008","article-title":"Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn\u2019s disease","volume":"147","author":"Takenaka","year":"2014","journal-title":"Gastroenterology."},{"key":"2023060914134201500_CIT0023","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/ibd.21300","article-title":"Endoscopic evaluation of Crohn\u2019s disease activity: comparison of the CDEIS and the SES-CD","volume":"16","author":"Sipponen","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"2023060914134201500_CIT0024","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"2023060914134201500_CIT0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bpg.2016.09.005","article-title":"Complications of diagnostic colonoscopy, upper endoscopy, and enteroscopy","volume":"30","author":"Levy","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"2023060914134201500_CIT0026","doi-asserted-by":"crossref","first-page":"e6635","DOI":"10.1097\/MD.0000000000006635","article-title":"Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: a STROBE-compliant retrospective cohort study","volume":"96","author":"Otake","year":"2017","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"2023060914134201500_CIT0027","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5217\/ir.2021.00139","article-title":"Long-term clinical and real-world experience with Crohn\u2019s disease treated with anti-tumor necrosis factor-\u03b1 antibodies","volume":"20","author":"Otake","year":"2022","journal-title":"Intest Res"},{"issue":"1","key":"2023060914134201500_CIT0028","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41598-020-57508-7","article-title":"Serum C-reactive protein and albumin are useful biomarkers for tight control management of Crohn\u2019s disease in Japan","volume":"10","author":"Shiga","year":"2020","journal-title":"Sci Rep."},{"key":"2023060914134201500_CIT0029","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ajg.2017.464","article-title":"Utility of magnetic resonance enterography for small bowel endoscopic healing in patients with Crohn\u2019s disease","volume":"113","author":"Takenaka","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2023060914134201500_CIT0030","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease","volume":"18","author":"D\u2019Haens","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2023060914134201500_CIT0031","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/MIB.0b013e3182807577","article-title":"Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases","volume":"19","author":"Nancey","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2023060914134201500_CIT0032","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide Crohn\u2019s disease into ileum-dominant and isolated colonic diseases?","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023060914134201500_CIT0033","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00535-018-1482-y","article-title":"Crohn\u2019s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan","volume":"54","author":"Yasukawa","year":"2019","journal-title":"J Gastroenterol."},{"key":"2023060914134201500_CIT0034","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/gutjnl-2012-303958","article-title":"Recent advances: personalised use of current Crohn\u2019s disease therapeutic options","volume":"62","author":"Vermeire","year":"2013","journal-title":"Gut."},{"key":"2023060914134201500_CIT0035","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/apt.16232","article-title":"Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing in Crohn\u2019s disease","volume":"53","author":"Lafeuille","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"2023060914134201500_CIT0036","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/ecco-jcc\/jjac072","article-title":"Intestinal Ultrasound Early on in Treatment Follow-up Predicts Endoscopic Response to Anti-TNF\u03b1 Treatment in Crohn\u2019s Disease","volume":"16","author":"de Voogd","year":"2022","journal-title":"J Crohns Colitis"}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otad028\/50423004\/otad028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/5\/3\/otad028\/50516237\/otad028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/5\/3\/otad028\/50516237\/otad028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T19:48:40Z","timestamp":1702496920000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otad028\/7176095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otad028","relation":{},"ISSN":["2631-827X"],"issn-type":[{"type":"electronic","value":"2631-827X"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,5,23]]},"article-number":"otad028"}}